Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.
The product offerings of the company can be classified into two major categories:
- APIs: Active Pharmaceutical Ingredient (API) is the biologically active component of a drug product (tablet, capsule, cream, injectable) that produces the intended effects.
- Finished Pharmaceutical Formulations: Finished pharmaceutical formulations are therapeutic drugs available in different dosage forms.
The product portfolio consists of 429 products, as on January 31, 2023. They operate under different brand names across the globe. As on January 31, 2023, the company has 295 products registered in a total of 13 countries. As on January 31, 2023, a total of 134 ;products are under the process of registration in 16 countries.
As on January 31, 2023, Remus Pharmaceuticals had business-to-business supply agreements with 58 domestic distributors and 139 international distributors for distribution and/or contract manufacturing supply.
The company has cultivated strong and dependable customer relationships and its clients are spread in more than 20 countries. These clients range from Generic distributors, regional distributors, and Multinational distributors to Hospitals and Clinics.
Remus Pharmaceuticals IPO Details
| IPO Date | May 17, 2023 to May 19, 2023 |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price | ₹1150 to ₹1229 per share |
| Lot Size | 100 Shares |
| Total Issue Size | 388,000 shares (aggregating up to ₹47.69 Cr) |
| Fresh Issue | 388,000 shares (aggregating up to ₹47.69 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
Remus Pharmaceuticals IPO Reservation
| QIB Shares Offered | Not more than 50% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| Market Maker portion | 19,500 shares (Sunflower Broking) |
Remus Pharmaceuticals IPO Tentative Timetable
Remus Pharmaceuticals IPO opens on May 17, 2023, and closes on May 19, 2023.
| Event | Tentative Date |
|---|---|
| Opening Date | May 17, 2023 |
| Closing Date | May 19, 2023 |
| Basis of Allotment | May 24, 2023 |
| Initiation of Refunds | May 25, 2023 |
| Credit of Shares to Demat | May 26, 2023 |
| Listing Date | May 29, 2023 |
| UPI Mandate Confirmation Cut-Off Time | 5.00 PM on the issue closing day |
Remus Pharmaceuticals IPO Lot Size
The Remus Pharmaceuticals IPO lot size is 100 shares.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 100 | ₹122,900 |
| Retail (Max) | 1 | 100 | ₹122,900 |
| HNI (Min) | 2 | 200 | ₹245,800 |
| Lot Size Calculator |
Remus Pharmaceuticals IPO Promoter Holding
Mr. Arpit Deepakkumar Shah, Ms. Roma Vinodbhai Shah, Mr. Swapnil Jatinbhai Shah, and Mrs. Anar Swapnil Shah are the Promoters of the company.
| Pre Issue Share Holding | 92.82% |
| Post Issue Share Holding |
Company Financials
| Period Ended | Total Assets | Total Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 31-Mar-20 | 530.36 | 1,276.89 | 81.16 | 202.03 | 201.03 | 35.93 |
| 31-Mar-21 | 1,104.96 | 1,922.45 | 102.58 | 304.61 | 303.61 | 27.89 |
| 31-Mar-22 | 1,590.93 | 2,543.71 | 338.57 | 643.17 | 543.17 | 19.17 |
| 31-Dec-22 | 3,352.96 | 3,361.20 | 643.90 | 1,712.07 | 1,603.57 | 947.45 |
| Amount in ₹ Lakhs |
Objects of the Issue
The Issue Proceeds from the Fresh Issue will be utilized towards the following objects:
- To Meet Working Capital Requirements
- Funding investments for acquisitions and general corporate purposes
- To meet Public Issue Expenses
Remus Pharmaceuticals IPO Prospectus
Company Contact Information
Remus Pharmaceuticals Limited
1101 to 1103, South Tower, One 42,
B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli bopal Road, Ahmedabad – 380054
Phone: +079- 2999 9857
Email: cs@remuspharma.com
Website: http://www.remuspharma.com/
Remus Pharmaceuticals IPO Registrar
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: remuspharmaceuticals.ipo@linkintime.co.in
Website: https://linkintime.co.in/